Arrhenius Stability Testing
Also known as: Arrhenius model, shelf-life prediction, degradation kinetics
Arrhenius stability testing predicts pharmaceutical product shelf-life by conducting accelerated degradation studies at elevated temperatures and using the Arrhenius equation to extrapolate to storage conditions. Based on Svante Arrhenius's 1889 equation relating reaction rate to temperature, this method is regulatory standard for establishing expiration dates.
Key highlights
- Rapid stability assessment: high-temperature data collected in months predict years of shelf-life
- Scientifically grounded in chemical kinetics; applicable to most pharmaceuticals
- Regulatory acceptance: required by FDA and EMA for drug registration
- Enables rational formulation optimization by identifying degradation pathways
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use Arrhenius testing to predict pharmaceutical shelf-life during product development and stability assessment. Required by FDA, EMA, and ICH guidelines for establishing expiration dates.
Strengths & limitations
- Rapid stability assessment: high-temperature data collected in months predict years of shelf-life
- Scientifically grounded in chemical kinetics; applicable to most pharmaceuticals
- Regulatory acceptance: required by FDA and EMA for drug registration
- Enables rational formulation optimization by identifying degradation pathways
- Assumes Arrhenius model holds; at extreme temperatures, non-Arrhenius behavior may occur
- Primary degradation pathway at high temperature may differ from low temperature; predictions may be inaccurate
- Ignores physical changes (crystallization, moisture uptake) that affect product quality but not assay
- Activation energy estimation depends on data quality and temperature range used
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What is the activation energy (Ea) and why does it matter?
Ea is the energy barrier a molecule must overcome to degrade. Higher Ea means degradation slows more steeply with cooling, so high-temperature predictions are more conservative. Lower Ea means degradation rate doesn't change much with temperature; Arrhenius predictions are more sensitive to exact temperature.
What temperatures should I use for Arrhenius testing?
FDA recommends 30°C (realistic), 40°C (accelerated), and 50°C (highly accelerated). Some use 60°C for very stable products. Temperature choice depends on expected Ea; very stable products need higher temperatures to generate sufficient degradation data.
What is the difference between zero and first-order kinetics?
Zero-order: rate is constant over time; plot amount degraded versus time (linear). First-order: rate slows as drug remains; plot ln(amount) versus time (linear). Kinetic order depends on degradation mechanism; always test both models and choose based on data fit.
How reliable is Arrhenius extrapolation?
Typically within 10-20% of real-time data if assumptions hold. However, if degradation mechanism changes with temperature or physical factors (moisture, crystallization) interfere, predictions can be significantly off. Always validate with long-term stability data when possible.
Sources
- 1.Arrhenius, S. (1889). Über die Reaktionsgeschwindigkeit bei der Inversion von Rohrzucker durch Säuren. Zeitschrift für Physikalische Chemie, 4, 226-248.
- 2.Carstensen, J. T. (1995). Drug stability: principles and practices. New York: Marcel Dekker.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). Arrhenius Stability. ScholarGate. https://scholargate.app/pharmacology/arrhenius-stability